| Richard L Jahnle, MD | |
|
2010 West Chester Pike, Wellness Center; Suite 310, Havertown, PA 19083-2737 | |
| (610) 446-2260 | |
| (610) 446-3360 |
| Full Name | Richard L Jahnle |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 42 Years |
| Location | 2010 West Chester Pike, Havertown, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083619878 | NPI | - | NPPES |
| 180008668 | Other | PA | RAILROAD MEDICARE |
| 23-2075896 | Other | PA | TAX ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD0290208E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Delaware County Memorial Hospital | Drexel hill, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Richard L Jahnle Md Pc | 0244492882 | 5 |
News Archive
In mid-March, we announced the availability of an anti-coronavirus antibody shown to recognize SARS-CoV-2 (also referred to as 2019-nCoV or COVID-19). The anti-SARS clone, CR3022, was first described in 2006, and in early 2020, researchers showed the clone has high affinity for the then-termed 2019-nCoV. Scientists worldwide are now exploring this antibody as a candidate for mono- as well as combination-therapy development.
NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.
Revealing these distinct - but often overlapping - patterns of neural activity represents a significant step in understanding how the brain translates complex signals from odorant receptors in the nose into odor perception in the brain, the researchers said.
Kaiser Permanente together with the National Patient Safety Foundation and the National Association of Public Hospitals and Health Systems today announced the "Patient Safety Initiative at America's Public Hospitals." This two-year program is designed to enhance patient safety programs at public hospitals to ensure safe, high-quality care for vulnerable and low-income populations that depend on publicly supported health care institutions for medical care.
› Verified 9 days ago
| Entity Name | Richard L Jahnle Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689949067 PECOS PAC ID: 0244492882 Enrollment ID: O20120427000316 |
News Archive
In mid-March, we announced the availability of an anti-coronavirus antibody shown to recognize SARS-CoV-2 (also referred to as 2019-nCoV or COVID-19). The anti-SARS clone, CR3022, was first described in 2006, and in early 2020, researchers showed the clone has high affinity for the then-termed 2019-nCoV. Scientists worldwide are now exploring this antibody as a candidate for mono- as well as combination-therapy development.
NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.
Revealing these distinct - but often overlapping - patterns of neural activity represents a significant step in understanding how the brain translates complex signals from odorant receptors in the nose into odor perception in the brain, the researchers said.
Kaiser Permanente together with the National Patient Safety Foundation and the National Association of Public Hospitals and Health Systems today announced the "Patient Safety Initiative at America's Public Hospitals." This two-year program is designed to enhance patient safety programs at public hospitals to ensure safe, high-quality care for vulnerable and low-income populations that depend on publicly supported health care institutions for medical care.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard L Jahnle, MD 2010 West Chester Pike, Wellness Center; Suite 310, Havertown, PA 19083-2737 Ph: (610) 446-2260 | Richard L Jahnle, MD 2010 West Chester Pike, Wellness Center; Suite 310, Havertown, PA 19083-2737 Ph: (610) 446-2260 |
News Archive
In mid-March, we announced the availability of an anti-coronavirus antibody shown to recognize SARS-CoV-2 (also referred to as 2019-nCoV or COVID-19). The anti-SARS clone, CR3022, was first described in 2006, and in early 2020, researchers showed the clone has high affinity for the then-termed 2019-nCoV. Scientists worldwide are now exploring this antibody as a candidate for mono- as well as combination-therapy development.
NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.
Revealing these distinct - but often overlapping - patterns of neural activity represents a significant step in understanding how the brain translates complex signals from odorant receptors in the nose into odor perception in the brain, the researchers said.
Kaiser Permanente together with the National Patient Safety Foundation and the National Association of Public Hospitals and Health Systems today announced the "Patient Safety Initiative at America's Public Hospitals." This two-year program is designed to enhance patient safety programs at public hospitals to ensure safe, high-quality care for vulnerable and low-income populations that depend on publicly supported health care institutions for medical care.
› Verified 9 days ago
Michael A Negrey, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 56 W Eagle Rd, Havertown, PA 19083 Phone: 610-449-4336 Fax: 610-446-1735 | |
Paul Ezell, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2010 W Chester Pike, Havertown, PA 19083 Phone: 610-446-2260 Fax: 610-446-3360 | |
Dr. Robert David Lehman Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 31 S Eagle Rd, Suite 107, Havertown, PA 19083 Phone: 610-446-3006 | |
Nestor Biletsky, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2010 W Chester Pike Ste 310, Havertown, PA 19083 Phone: 610-446-2260 Fax: 610-446-3360 | |
Dr. John N. Negrey Jr., M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 56 W Eagle Rd, Havertown, PA 19083 Phone: 610-449-4336 Fax: 610-446-1735 | |
John J Lee, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2050 W Chester Pike, Suite 100, Havertown, PA 19083 Phone: 610-789-6701 Fax: 610-789-6704 |